[To give or not to give? Towards the indication of CSE inhibitors ("statins")].
The indication for HMG-CoA-reductase-inhibitors (CSE inhibitors, "statins") for primary prevention of atherosclerosis requires a careful risk/benefit calculation. For this, the PROCAM and SCORE risk scores offer validated, hands on decision support tools. In patients with manifest atherosclerosis and diabetes mellitus statins are indicated regardless of the serum cholesterol level.
Teichert
Matthias
M
Institut für Klinische Pharmakologie, Medizinische Hochschule Hannover, Hannover. Klinische.Pharmakologie@mh-hannover.de
Lüer
Apothekerin Katrin
AK
Stichtenoth
Dirk O
DO
D050197:Atherosclerosis / Q000188:drug therapy*; D002784:Cholesterol / Q000097:blood; D048909:Diabetes Complications / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol